Evan R. Delgado, PhD

Research Assistant Professor of Pathology, Division of Experimental Pathology

Dr. Delgado is a member of the Division of Experimental Pathology.

Education & Training
BS - 2009, State University of New York at Albany
PhD - 2014, University of Pittsburgh School of Medicine
Research Interests

My overall goal is to challenge the unmet need of effective targeted therapies for Hepatocellular Carcinoma (HCC) by innovating a patient derived xenograft model that streamlines preclinical drug development. HCC is the 5th most common cause of cancer-related death in the United States with an estimated 32,000 annual deaths. Insufficient therapies that minimally extend overall survival (e.g., Sorafenib and Levatinib) and a lack of resources (e.g., healthy donor organs for transplantation) have limited disease management. I aim to clarify the underlying mechanisms promoting HCC oncogenesis.

An explanation for the poor state of HCC therapeutics may be the ineffective translation of pre-clinical animal models to human disease. In fact, only about 1/3 of therapeutic approaches generated using animal models move to Phase I trials, and, of those that make it, only 8% pass. Improvements in this space are desperately needed to translate findings into practical therapeutic options.

My recent work has demonstrated the involvement of IQGAP1, a scaffold protein, and its role in hepatocellular biology. I found that IQGAP1 promotes YAP1 signaling in early stage HCC. Thus, the use of humanized animal models will provide a platform to target the IQGAP1-YAP1 network and provide additional opportunities to study other subjects such as how the immune microenvironment contributes to disease pathogenesis.

Representative Publications
  • Delgado ER*, Erickson HL*, Tao J, Monga SP, Duncan AW, Anakk S. Scaffolding Protein IQGAP1 is Dispensable But Its Overexpression Promotes Hepatocellular Carcinoma via YAP1 Signaling. Mol Cell Biol. 2021 Feb 1;. doi: 10.1128/MCB.00596-20PMID: 33526450.
  • Takeishi K, Collin de l'Hortet A, Wang Y, Handa K, Guzman-Lepe J, Matsubara K, Morita K, Jang S, Haep N, Florentino RM, Yuan F, Fukumitsu K, Tobita K, Sun W, Franks J, Delgado ER, Shapiro EM, Fraunhoffer NA, Duncan AW, Yagi H, Mashimo T, Fox IJ, Soto-Gutierrez A. Assembly and Function of a Bioengineered Human Liver for Transplantation Generated Solely from Induced Pluripotent Stem Cells. Cell Rep. 2020;31(9):107711. doi: 10.1016/j.celrep.2020.107711PMID: 32492423.
  • {Stahl, 2020 #1280}Stahl, E. C., Delgado, E. R., Alencastro, F., LoPresti, S. T., Wilkinson, P. D., Roy, N., Haschak, M. J., Skillen, C. D., Monga, S. P., Duncan, A. W., Brown, B. N. Inflammation and Ectopic Fat Deposition in the Aging Murine Liver Is Influenced by CCR2. Am J Pathol. 2020 Feb;190(2):372-387. doi: 10.1016/j.ajpath.2019.10.016. Epub 2019 Dec 13. PMID: 31843499PMCID: PMC7013280.
  • Wilkinson PD, Alencastro F, Delgado ER, Leek MP, Weirich MP, Otero PA, Roy N, Brown WK, Oertel M, Duncan AW. Polyploid Hepatocytes Facilitate Adaptation and Regeneration to Chronic Liver Injury. Am J Pathol. 2019 Jun;189(6):1241-1255. doi: 10.1016/j.ajpath.2019.02.008. Epub 2019 Mar 28. PMID: 30928253PMCID: PMC6547059.
  • Wilkinson PD, Delgado ER, Alencastro F, Leek MP, Roy N, Weirich MP, Stahl EC, Otero PA, Chen MI, Brown WK, Duncan AW. The Polyploid State Restricts Hepatocyte Proliferation and Liver Regeneration in Mice. Hepatology. 2019 Mar;69(3):1242-1258. doi: 10.1002/hep.30286. Epub 2019 Feb 15. PMID: 30244478PMCID: PMC6532408.
  • Hsu SH*, Delgado ER*, Otero PA, Teng KY, Kutay H, Meehan KM, Moroney JB, Monga JK, Hand NJ, Friedman JR, Ghoshal K, Duncan AW. MicroRNA-122 regulates polyploidization in the murine liver. Hepatology. 2016 Aug;64(2):599-615. doi: 10.1002/hep.28573. Epub 2016 May 12. PMID: 27016325PMCID: PMC4956491.
  • Delgado E*, Boisen MM*, Laskey R*, Chen R, Song C, Sallit J, Yochum ZA, Andersen CL, Sikora MJ, Wagner J, Safe S, Elishaev E, Lee A, Edwards RP, Haluska P, Tseng G, Schurdak M, Oesterreich S. High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. Gynecol Oncol. 2016 May;141(2):348-356. doi: 10.1016/j.ygyno.2016.02.030. Epub 2016 Mar 11. PMID: 26946093PMCID: PMC5154956.
  • Delgado E, Okabe H, Preziosi M, Russell JO, Alvarado TF, Oertel M, Nejak-Bowen KN, Zhang Y, Monga SP. Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model. J Hepatol. 2015 Feb;62(2):380-7. doi: 10.1016/j.jhep.2014.10.021. Epub 2014 Oct 18. PMID: 25457204PMCID: PMC4300253.
  • Delgado ER, Yang J, So J, Leimgruber S, Kahn M, Ishitani T, Shin D, Mustata Wilson G, Monga SP. Identification and characterization of a novel small-molecule inhibitor of β-catenin signaling. Am J Pathol. 2014 Jul;184(7):2111-22. doi: 10.1016/j.ajpath.2014.04.002. Epub 2014 May 10. PMID: 24819961PMCID: PMC4076560.
  • Okabe H, Delgado E, Lee JM, Yang J, Kinoshita H, Hayashi H, Tsung A, Behari J, Beppu T, Baba H, Monga SP. Role of leukocyte cell-derived chemotaxin 2 as a biomarker in hepatocellular carcinoma. PLoS One. 2014;9(6):e98817. doi: 10.1371/journal.pone.0098817. eCollection 2014. PMID: 24892551PMCID: PMC4043833.
  • Delgado E, Bahal R, Yang J, Lee JM, Ly DH, Monga SP. β-Catenin knockdown in liver tumor cells by a cell permeable gamma guanidine-based peptide nucleic acid. Curr Cancer Drug Targets. 2013 Oct;13(8):867-78. PMID: 23822752PMCID: PMC4098753.